According to the company, the newly allowed claims include subject matter covering aspects of blood-based appendicitis testing.
A notice of allowance generally completes the substantive examination of a patent application. Following a notice of allowance, the normal process which results in final issuance of a US patent involves several administrative steps that are typically completed in due course following issuance of this notice.
Richard Donnelly, president and CEO of AspenBio Pharma, said: “This represents a major milestone in the development of our intellectual property for the appendicitis diagnostic technology. This official notice from the Patent Office represents a considerable achievement for our company and our goals.
“The issuance of this notice represents recognition of the patentability of our innovative technology and enhances the value of this important asset.”